Naproxen interferes with the assembly of Aβ oligomers implicated in Alzheimer's disease

Biophysical Journal

Volumn 100, Issue 8, 2011, Pages 2024-2032

  Kim, Seongwon ^a   Chang, Wenling E ^a,b   Kumar, Rashmi ^a   Klimov, Dmitri K ^a  

^a GEORGE MASON UNIVERSITY   (United States)

^b MITRE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959709938     PISSN: 00063495     EISSN: 15420086     Source Type: Journal    
DOI: 10.1016/j.bpj.2011.02.044     Document Type: Article

References (54)

1. Selkoe, D. J. 2003. Folding proteins in fatal ways. Nature. 426:900-904. (Pubitemid 38056883)
2. Dobson, C. M. 2003. Protein folding and misfolding. Nature. 426:884-890. (Pubitemid 38056880)
3. Hardy, J., and D. J. Selkoe. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:353-356. (Pubitemid 34790756)
4. Kirkitadze, M. D., G. Bitan, and D. B. Teplow. 2002. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J. Neurosci. Res. 69:567-577. (Pubitemid 34966869)
5. Murphy, R. M. 2002. Peptide aggregation in neurodegenerative disease. Annu. Rev. Biomed. Eng. 4:155-174. (Pubitemid 35217418)
6. Hardy, J. A., and G. A. Higgins. 1992. Alzheimer's disease: the amyloid cascade hypothesis. Science. 256:184-185.
7. Kayed, R., E. Head, C. G. Glabe. 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 300:486-489. (Pubitemid 36444329)
8. Haass, C., and D. J. Selkoe. 2007. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 8:101-112. (Pubitemid 46432529)
9. Gandy, S., A. J. Simon, M. E. Ehrlich. 2010. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann. Neurol. 68:220-230.
10. Shankar, G. M., S. Li, D. J. Selkoe. 2008. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14:837-842.
11. Carulla, N., G. L. Caddy, C. M. Dobson. 2005. Molecular recycling within amyloid fibrils. Nature. 436:554-558. (Pubitemid 41112928)
12. Cole, G. M., and S. A. Frautschy. 2010. Mechanisms of action of nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. CNS Neurol. Disord. Drug Targets. 9:140-148.
13. Vlad, S. C., D. R. Miller, D. T. Felson. 2008. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 70:1672-1677. (Pubitemid 351644133)
14. Imbimbo, B. P. 2009. An update on the efficacy of non-steroidal antiinflammatory drugs in Alzheimer's disease. Expert Opin. Investig. Drugs. 18:1147-1168.
15. Imbimbo, B. P., V. Solfrizzi, and F. Panza. 2010. Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Front. Aging Neurosci. 2:1-14.
16. Imbimbo, B. P. 2004. The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. Expert Opin. Investig. Drugs. 13:1469-1481. (Pubitemid 39530199)
17. Gasparini, L., E. Ongini, and G. Wenk. 2004. Non-steroidal antiinflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J. Neurochem. 91:521-536. (Pubitemid 39431148)
18. Varvel, N. H., K. Bhaskar, K. Herrup. 2009. NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J. Clin. Invest. 119:3692-3702.
19. Agdeppa, E. D., V. Kepe, J. R. Barrio. 2003. In vitro detection of (s)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-{6-[(2-[18F] fluoroethyl) (methyl) amino]-2-naphthyl}ethylidene) malononitrile. Neuroscience. 117:723-730. (Pubitemid 36263165)
20. LeVine, 3rd, H. 2005. Multiple ligand binding sites on Aβ (1-40) fibrils. Amyloid. 12:5-14.
21. Hirohata, M., K. Ono, M. Yamada. 2005. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's b-amyloid fibrils in vitro. Neuropharmacology. 49:1088-1099. (Pubitemid 41503307)
22. Ma, B., and R. Nussinov. 2006. Simulations as analytical tools to understand protein aggregation and predict amyloid conformation. Curr. Opin. Chem. Biol. 10:445-452. (Pubitemid 44389918)
23. Cecchini, M., F. Rao, A. Caflisch. 2004. Replica exchange molecular dynamics simulations of amyloid peptide aggregation. J. Chem. Phys. 121:10748-10756. (Pubitemid 40001622)
24. Nguyen, P. H., M. S. Li, D. Thirumalai. 2007. Monomer adds to preformed structured oligomers of Abeta-peptides by a two-stage dock-lock mechanism. Proc. Natl. Acad. Sci. USA. 104:111-116. (Pubitemid 46067993)
25. Krone, M. G., L. Hua, J. E. Shea. 2008. Role of water in mediating the assembly of Alzheimer amyloid-beta Abeta16-22 protofilaments. J. Am. Chem. Soc. 130:11066-11072. 10.1021/ja8017303.
26. Takeda, T., and D. K. Klimov. 2009. Replica exchange simulations of the thermodynamics of Abeta fibril growth. Biophys. J. 96:442-452.
27. Sgourakis, N. G., Y. Yan, A. E. Garcia. 2007. The Alzheimer's peptides Abeta40 and 42 adopt distinct conformations in water: a combined MD/NMR study. J. Mol. Biol. 368:1448-1457. (Pubitemid 46617600)
28. Yang, M., and D. B. Teplow. 2008. Amyloid β-protein monomer folding: free-energy surfaces reveal alloform-specific differences. J. Mol. Biol. 384:450-464.
29. Lu, Y., P. Derreumaux, G. Wei. 2009. Thermodynamics and dynamics of amyloid peptide oligomerization are sequence dependent. Proteins. 75:954-963.
30. Bellesia, G., and J.-E. Shea. 2009. What determines the structure and stability of KFFE monomers, dimers, and protofibrils? Biophys. J. 96:875-886.
31. Takeda, T., and D. K. Klimov. 2009. Interpeptide interactions induce helix to strand structural transition in Abeta peptides. Proteins. 77:1-13.
32. Anand, P., F. S. Nandel, and U. H. E. Hansmann. 2008. The Alzheimer β-amyloid (Abeta (1-39)) dimer in an implicit solvent. J. Chem. Phys. 129:195102.
33. Urbanc, B., M. Betnel, D. B. Teplow. 2010. Elucidation of amyloid β-protein oligomerization mechanisms: discrete molecular dynamics study. J. Am. Chem. Soc. 132:4266-4280.
34. Takeda, T., W. E. Chang, D. K. Klimov. 2010. Binding of non-steroidal anti-inflammatory drugs to Abeta fibril. Proteins. 78:2859-2860.
35. Takeda, T., R. Kumar, D. K. Klimov. 2010. Nonsteroidal antiinflammatory drug naproxen destabilizes Aβ amyloid fibrils: a molecular dynamics investigation. J. Phys. Chem. B. 114:15394-15402.
36. Brooks, B. R., R. E. Bruccoler, M. Karplus. 1982. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 4:187-217.
37. Ferrara, P., J. Apostolakis, and A. Caflisch. 2002. Evaluation of a fast implicit solvent model for molecular dynamics simulations. Proteins. 46:24-33. (Pubitemid 34033573)
38. Takeda, T., and D. K. Klimov. 2009. Probing energetics of Abeta fibril elongation by molecular dynamics simulations. Biophys. J. 96:4428-4437.
39. Hou, L., H. Shao, M. G. Zagorski. 2004. Solution NMR studies of the Aβ (1-40) and Aβ (1-42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. J. Am. Chem. Soc. 126:1992-2005. (Pubitemid 38228879)
40. Takeda, T., and D. K. Klimov. 2009. Probing the effect of amino-terminal truncation for Abeta1-40 peptides. J. Phys. Chem. B. 113:6692-6702.
41. Thomas, T., T. G. Nadackal, and K. Thomas. 2001. Aspirin and nonsteroidal anti-inflammatory drugs inhibit amyloid-β aggregation. Neuroreport. 12:3263-3267. (Pubitemid 33014359)
42. Sugita, Y., and Y. Okamoto. 1999. Replica-exchange molecular dynamics method for protein folding. Chem. Phys. Lett. 114:141-151. (Pubitemid 129556751)
43. Chang, W. E., T. Takeda, D. K. Klimov. 2010. Molecular dynamics simulations of anti-aggregation effect of ibuprofen. Biophys. J. 98:2662-2670.
44. Kabsch, W., and C. Sander. 1983. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers. 22:2577-2637.
45. Kim, S., T. Takeda, and D. K. Klimov. 2010. Mapping conformational ensembles of aβ oligomers in molecular dynamics simulations. Biophys. J. 99:1949-1958.
46. Ferrenberg, A. M., and R. H. Swendsen. 1989. Optimized Monte Carlo data analysis. Phys. Rev. Lett. 63:1195-1198.
47. Morris, G. M., R. Huey, A. J. Olson. 2009. AutoDock4 and Auto-DockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 30:2785-2791.
48. Petkova, A. T., W.-M. Yau, and R. Tycko. 2006. Experimental constraints on quaternary structure in Alzheimer's β-amyloid fibrils. Biochemistry. 45:498-512. (Pubitemid 43100415)
49. Kim, S., T. Takeda, and D. K. Klimov. 2010. Globular state in the oligomers formed by Abeta peptides. J. Chem. Phys. 132:225101.
50. Convertino, M., R. Pellarin, A. Caflisch. 2009. 9, 10-Anthraquinone hinders β-aggregation: how does a small molecule interfere with Abeta-peptide amyloid fibrillation? Protein Sci. 18:792-800.
51. Raman, E. P., T. Takeda, and D. K. Klimov. 2009. Molecular dynamics simulations of Ibuprofen binding to Abeta peptides. Biophys. J. 97:2070-2079.
52. Wu, C., M. Biancalana, J. E. Shea. 2009. Binding modes of thioflavin-T to the single-layer β-sheet of the peptide self-assembly mimics. J. Mol. Biol. 394:627-633.
53. Yang, F., G. P. Lim, G. M. Cole. 2005. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280:5892-5901. (Pubitemid 40280072)
54. Chen, J., A. H. Armstrong, M. H. Hecht. 2010. Small molecule microarrays enable the discovery of compounds that bind the Alzheimer's Aβ peptide and reduce its cytotoxicity. J. Am. Chem. Soc. 132:17015-17022.